About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​

  1. The ABPI and the BioIndustry Association (BIA) have worked across industry and with regulators and government to map out the challenges and opportunities presented by Brexit to the UK's £30 billion Life Sciences industry.

    In September 2016, ABPI, BIA and PwC published 'Maintaining and growing the UK’s world leading Life Sciences sector in the context of leaving the EU'. This details key Brexit priorities for the sector.

    In December 2017, ABPI and BIA also published a detailed impact assesment by the Office of Health Economics on the 'Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market'.
     
  2. The ABPI are also part of a joint UK / EU coalition of eleven life sciences industry bodies working together on Brexit.

    In December 2017, this group published 'UK’s Exit from the European Union'. This position paper details key Brexit priorites for the European life sciences sector as a whole.

    This coalition have today also published a statement that is available online via EFPIA.

Media enquiries


+44 (0) 20 7747 7147​​